Global Next Generation Antibody Therapeutics Market 2024 by Company, Regions, Type and Application, Forecast to 2030
1 Market Overview
- 1.1 Product Overview and Scope
- 1.2 Market Estimation Caveats and Base Year
- 1.3 Classification of Next Generation Antibody Therapeutics by Type
- 1.3.1 Overview: Global Next Generation Antibody Therapeutics Market Size by Type: 2019 Versus 2023 Versus 2030
- 1.3.2 Global Next Generation Antibody Therapeutics Consumption Value Market Share by Type in 2023
- 1.3.3 Antibody Drug Conjugate (ADC)
- 1.3.4 Bispecific Antibody (BsAb)
- 1.4 Global Next Generation Antibody Therapeutics Market by Application
- 1.4.1 Overview: Global Next Generation Antibody Therapeutics Market Size by Application: 2019 Versus 2023 Versus 2030
- 1.4.2 Cancer
- 1.4.3 Haemophilia
- 1.4.4 Other Non-Cancer Diseases
- 1.5 Global Next Generation Antibody Therapeutics Market Size & Forecast
- 1.6 Global Next Generation Antibody Therapeutics Market Size and Forecast by Region
- 1.6.1 Global Next Generation Antibody Therapeutics Market Size by Region: 2019 VS 2023 VS 2030
- 1.6.2 Global Next Generation Antibody Therapeutics Market Size by Region, (2019-2030)
- 1.6.3 North America Next Generation Antibody Therapeutics Market Size and Prospect (2019-2030)
- 1.6.4 Europe Next Generation Antibody Therapeutics Market Size and Prospect (2019-2030)
- 1.6.5 Asia-Pacific Next Generation Antibody Therapeutics Market Size and Prospect (2019-2030)
- 1.6.6 South America Next Generation Antibody Therapeutics Market Size and Prospect (2019-2030)
- 1.6.7 Middle East & Africa Next Generation Antibody Therapeutics Market Size and Prospect (2019-2030)
2 Company Profiles
- 2.1 Roche
- 2.1.1 Roche Details
- 2.1.2 Roche Major Business
- 2.1.3 Roche Next Generation Antibody Therapeutics Product and Solutions
- 2.1.4 Roche Next Generation Antibody Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
- 2.1.5 Roche Recent Developments and Future Plans
- 2.2 Amgen
- 2.2.1 Amgen Details
- 2.2.2 Amgen Major Business
- 2.2.3 Amgen Next Generation Antibody Therapeutics Product and Solutions
- 2.2.4 Amgen Next Generation Antibody Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
- 2.2.5 Amgen Recent Developments and Future Plans
- 2.3 Pfizer
- 2.3.1 Pfizer Details
- 2.3.2 Pfizer Major Business
- 2.3.3 Pfizer Next Generation Antibody Therapeutics Product and Solutions
- 2.3.4 Pfizer Next Generation Antibody Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
- 2.3.5 Pfizer Recent Developments and Future Plans
- 2.4 Takeda
- 2.4.1 Takeda Details
- 2.4.2 Takeda Major Business
- 2.4.3 Takeda Next Generation Antibody Therapeutics Product and Solutions
- 2.4.4 Takeda Next Generation Antibody Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
- 2.4.5 Takeda Recent Developments and Future Plans
- 2.5 Daiichi Sankyo
- 2.5.1 Daiichi Sankyo Details
- 2.5.2 Daiichi Sankyo Major Business
- 2.5.3 Daiichi Sankyo Next Generation Antibody Therapeutics Product and Solutions
- 2.5.4 Daiichi Sankyo Next Generation Antibody Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
- 2.5.5 Daiichi Sankyo Recent Developments and Future Plans
- 2.6 Seagen
- 2.6.1 Seagen Details
- 2.6.2 Seagen Major Business
- 2.6.3 Seagen Next Generation Antibody Therapeutics Product and Solutions
- 2.6.4 Seagen Next Generation Antibody Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
- 2.6.5 Seagen Recent Developments and Future Plans
- 2.7 Astellas
- 2.7.1 Astellas Details
- 2.7.2 Astellas Major Business
- 2.7.3 Astellas Next Generation Antibody Therapeutics Product and Solutions
- 2.7.4 Astellas Next Generation Antibody Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
- 2.7.5 Astellas Recent Developments and Future Plans
- 2.8 Immunomedics
- 2.8.1 Immunomedics Details
- 2.8.2 Immunomedics Major Business
- 2.8.3 Immunomedics Next Generation Antibody Therapeutics Product and Solutions
- 2.8.4 Immunomedics Next Generation Antibody Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
- 2.8.5 Immunomedics Recent Developments and Future Plans
- 2.9 GSK
- 2.9.1 GSK Details
- 2.9.2 GSK Major Business
- 2.9.3 GSK Next Generation Antibody Therapeutics Product and Solutions
- 2.9.4 GSK Next Generation Antibody Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
- 2.9.5 GSK Recent Developments and Future Plans
- 2.10 Immunocore
- 2.10.1 Immunocore Details
- 2.10.2 Immunocore Major Business
- 2.10.3 Immunocore Next Generation Antibody Therapeutics Product and Solutions
- 2.10.4 Immunocore Next Generation Antibody Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
- 2.10.5 Immunocore Recent Developments and Future Plans
- 2.11 ADC Therapeutics
- 2.11.1 ADC Therapeutics Details
- 2.11.2 ADC Therapeutics Major Business
- 2.11.3 ADC Therapeutics Next Generation Antibody Therapeutics Product and Solutions
- 2.11.4 ADC Therapeutics Next Generation Antibody Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
- 2.11.5 ADC Therapeutics Recent Developments and Future Plans
3 Market Competition, by Players
- 3.1 Global Next Generation Antibody Therapeutics Revenue and Share by Players (2019-2024)
- 3.2 Market Share Analysis (2023)
- 3.2.1 Market Share of Next Generation Antibody Therapeutics by Company Revenue
- 3.2.2 Top 3 Next Generation Antibody Therapeutics Players Market Share in 2023
- 3.2.3 Top 6 Next Generation Antibody Therapeutics Players Market Share in 2023
- 3.3 Next Generation Antibody Therapeutics Market: Overall Company Footprint Analysis
- 3.3.1 Next Generation Antibody Therapeutics Market: Region Footprint
- 3.3.2 Next Generation Antibody Therapeutics Market: Company Product Type Footprint
- 3.3.3 Next Generation Antibody Therapeutics Market: Company Product Application Footprint
- 3.4 New Market Entrants and Barriers to Market Entry
- 3.5 Mergers, Acquisition, Agreements, and Collaborations
4 Market Size Segment by Type
- 4.1 Global Next Generation Antibody Therapeutics Consumption Value and Market Share by Type (2019-2024)
- 4.2 Global Next Generation Antibody Therapeutics Market Forecast by Type (2025-2030)
5 Market Size Segment by Application
- 5.1 Global Next Generation Antibody Therapeutics Consumption Value Market Share by Application (2019-2024)
- 5.2 Global Next Generation Antibody Therapeutics Market Forecast by Application (2025-2030)
6 North America
- 6.1 North America Next Generation Antibody Therapeutics Consumption Value by Type (2019-2030)
- 6.2 North America Next Generation Antibody Therapeutics Market Size by Application (2019-2030)
- 6.3 North America Next Generation Antibody Therapeutics Market Size by Country
- 6.3.1 North America Next Generation Antibody Therapeutics Consumption Value by Country (2019-2030)
- 6.3.2 United States Next Generation Antibody Therapeutics Market Size and Forecast (2019-2030)
- 6.3.3 Canada Next Generation Antibody Therapeutics Market Size and Forecast (2019-2030)
- 6.3.4 Mexico Next Generation Antibody Therapeutics Market Size and Forecast (2019-2030)
7 Europe
- 7.1 Europe Next Generation Antibody Therapeutics Consumption Value by Type (2019-2030)
- 7.2 Europe Next Generation Antibody Therapeutics Consumption Value by Application (2019-2030)
- 7.3 Europe Next Generation Antibody Therapeutics Market Size by Country
- 7.3.1 Europe Next Generation Antibody Therapeutics Consumption Value by Country (2019-2030)
- 7.3.2 Germany Next Generation Antibody Therapeutics Market Size and Forecast (2019-2030)
- 7.3.3 France Next Generation Antibody Therapeutics Market Size and Forecast (2019-2030)
- 7.3.4 United Kingdom Next Generation Antibody Therapeutics Market Size and Forecast (2019-2030)
- 7.3.5 Russia Next Generation Antibody Therapeutics Market Size and Forecast (2019-2030)
- 7.3.6 Italy Next Generation Antibody Therapeutics Market Size and Forecast (2019-2030)
8 Asia-Pacific
- 8.1 Asia-Pacific Next Generation Antibody Therapeutics Consumption Value by Type (2019-2030)
- 8.2 Asia-Pacific Next Generation Antibody Therapeutics Consumption Value by Application (2019-2030)
- 8.3 Asia-Pacific Next Generation Antibody Therapeutics Market Size by Region
- 8.3.1 Asia-Pacific Next Generation Antibody Therapeutics Consumption Value by Region (2019-2030)
- 8.3.2 China Next Generation Antibody Therapeutics Market Size and Forecast (2019-2030)
- 8.3.3 Japan Next Generation Antibody Therapeutics Market Size and Forecast (2019-2030)
- 8.3.4 South Korea Next Generation Antibody Therapeutics Market Size and Forecast (2019-2030)
- 8.3.5 India Next Generation Antibody Therapeutics Market Size and Forecast (2019-2030)
- 8.3.6 Southeast Asia Next Generation Antibody Therapeutics Market Size and Forecast (2019-2030)
- 8.3.7 Australia Next Generation Antibody Therapeutics Market Size and Forecast (2019-2030)
9 South America
- 9.1 South America Next Generation Antibody Therapeutics Consumption Value by Type (2019-2030)
- 9.2 South America Next Generation Antibody Therapeutics Consumption Value by Application (2019-2030)
- 9.3 South America Next Generation Antibody Therapeutics Market Size by Country
- 9.3.1 South America Next Generation Antibody Therapeutics Consumption Value by Country (2019-2030)
- 9.3.2 Brazil Next Generation Antibody Therapeutics Market Size and Forecast (2019-2030)
- 9.3.3 Argentina Next Generation Antibody Therapeutics Market Size and Forecast (2019-2030)
10 Middle East & Africa
- 10.1 Middle East & Africa Next Generation Antibody Therapeutics Consumption Value by Type (2019-2030)
- 10.2 Middle East & Africa Next Generation Antibody Therapeutics Consumption Value by Application (2019-2030)
- 10.3 Middle East & Africa Next Generation Antibody Therapeutics Market Size by Country
- 10.3.1 Middle East & Africa Next Generation Antibody Therapeutics Consumption Value by Country (2019-2030)
- 10.3.2 Turkey Next Generation Antibody Therapeutics Market Size and Forecast (2019-2030)
- 10.3.3 Saudi Arabia Next Generation Antibody Therapeutics Market Size and Forecast (2019-2030)
- 10.3.4 UAE Next Generation Antibody Therapeutics Market Size and Forecast (2019-2030)
11 Market Dynamics
- 11.1 Next Generation Antibody Therapeutics Market Drivers
- 11.2 Next Generation Antibody Therapeutics Market Restraints
- 11.3 Next Generation Antibody Therapeutics Trends Analysis
- 11.4 Porters Five Forces Analysis
- 11.4.1 Threat of New Entrants
- 11.4.2 Bargaining Power of Suppliers
- 11.4.3 Bargaining Power of Buyers
- 11.4.4 Threat of Substitutes
- 11.4.5 Competitive Rivalry
12 Industry Chain Analysis
- 12.1 Next Generation Antibody Therapeutics Industry Chain
- 12.2 Next Generation Antibody Therapeutics Upstream Analysis
- 12.3 Next Generation Antibody Therapeutics Midstream Analysis
- 12.4 Next Generation Antibody Therapeutics Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
- 14.1 Methodology
- 14.2 Research Process and Data Source
Building on the huge success of monoclonal antibody therapeutics, the next generation of antibody-based products such as Antibody Drug Conjugate (ADC) and Bispecific Antibody (BsAb) is now opening up new opportunities.
According to our (Global Info Research) latest study, the global Next Generation Antibody Therapeutics market size was valued at US$ 12610 million in 2023 and is forecast to a readjusted size of USD 47260 million by 2030 with a CAGR of 21.0% during review period.
Global key players of next generation antibody therapeutics include Roche, Seagen, Amgen, Pfizer, Takeda, etc. The top two players hold a share over 70%. North America is the largest market, has a share about 65%, followed by Europe and Asia-Pacific, with share 16% and 15%, separately. In terms of product type, Antibody Drug Conjugate (ADC) is the largest segment, occupied for a share of 60%, and in terms of application, Cancer has a share about 66 percent.
This report is a detailed and comprehensive analysis for global Next Generation Antibody Therapeutics market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2024, are provided.
Key Features:
Global Next Generation Antibody Therapeutics market size and forecasts, in consumption value ($ Million), 2019-2030
Global Next Generation Antibody Therapeutics market size and forecasts by region and country, in consumption value ($ Million), 2019-2030
Global Next Generation Antibody Therapeutics market size and forecasts, by Type and by Application, in consumption value ($ Million), 2019-2030
Global Next Generation Antibody Therapeutics market shares of main players, in revenue ($ Million), 2019-2024
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Next Generation Antibody Therapeutics
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Next Generation Antibody Therapeutics market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Roche, Amgen, Pfizer, Takeda, Daiichi Sankyo, Seagen, Astellas, Immunomedics, GSK, Immunocore, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Next Generation Antibody Therapeutics market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segmentation
Next Generation Antibody Therapeutics market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Antibody Drug Conjugate (ADC)
Bispecific Antibody (BsAb)
Market segment by Application
Cancer
Haemophilia
Other Non-Cancer Diseases
Market segment by players, this report covers
Roche
Amgen
Pfizer
Takeda
Daiichi Sankyo
Seagen
Astellas
Immunomedics
GSK
Immunocore
ADC Therapeutics
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Next Generation Antibody Therapeutics product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Next Generation Antibody Therapeutics, with revenue, gross margin, and global market share of Next Generation Antibody Therapeutics from 2019 to 2024.
Chapter 3, the Next Generation Antibody Therapeutics competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Next Generation Antibody Therapeutics market forecast, by regions, by Type and by Application, with consumption value, from 2024 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Next Generation Antibody Therapeutics.
Chapter 13, to describe Next Generation Antibody Therapeutics research findings and conclusion.